Cullen Capital Management LLC Decreases Holdings in Pfizer Inc. $PFE

Cullen Capital Management LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 38.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,258,687 shares of the biopharmaceutical company’s stock after selling 1,384,891 shares during the quarter. Cullen Capital Management LLC’s holdings in Pfizer were worth $57,551,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the business. Curio Wealth LLC increased its stake in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares during the period. Grey Fox Wealth Advisors LLC purchased a new stake in Pfizer during the 3rd quarter valued at $29,000. Harbor Asset Planning Inc. bought a new stake in Pfizer in the 2nd quarter worth $29,000. Howard Hughes Medical Institute purchased a new position in shares of Pfizer in the second quarter valued at about $30,000. Finally, True Wealth Design LLC raised its stake in shares of Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 974 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 4.1%

NYSE PFE opened at $26.83 on Thursday. The firm has a market capitalization of $152.55 billion, a PE ratio of 19.73 and a beta of 0.47. The stock’s 50 day moving average is $25.57 and its 200 day moving average is $25.07. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The company’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.63 earnings per share. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is 126.47%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PFE. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 target price on shares of Pfizer in a report on Wednesday, November 5th. Morgan Stanley dropped their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $28.06.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 beat — Pfizer reported stronger‑than‑expected Q4 revenue and adjusted EPS, which underpinned the rally and reassures investors that legacy drugs (like Eliquis) are offsetting COVID declines. Reuters: Pfizer beats fourth-quarter profit estimates
• Positive Sentiment: GLP‑1 mid‑stage success — topline VESPER‑3 data for MET‑097i (monthly injectable) showed up to ~12.3% placebo‑adjusted weight loss and maintained weight loss after switching from weekly to monthly dosing, giving Pfizer a credible entrant in the high‑growth obesity market. Reuters: Pfizer’s experimental drug shows up to 12.3% weight loss
• Positive Sentiment: Longer‑term catalysts — analysts and commentators highlight Pfizer’s expanded oncology portfolio (including Seagen assets) and AI partnerships as multi‑year growth drivers that could meaningfully re‑rate the stock if late‑stage trials succeed. MarketBeat: Pfizer earnings & pipeline analysis
• Neutral Sentiment: Analyst stance is cautious — major firms (Goldman, Citi and others) are largely Neutral/Hold with price targets near the current level, reflecting upside from the pipeline but offset by near‑term headwinds. InsiderMonkey: Goldman Sachs maintains Neutral on Pfizer TipRanks: Citi Hold commentary
• Negative Sentiment: Guidance and margin pressure — Pfizer reiterated FY‑2026 guidance that implies EPS of ~$2.80–3.00 (around or slightly below consensus) and flagged near‑term profit declines, which keeps investors cautious on 2026 growth and margins. BusinessWire: Pfizer reaffirms 2026 guidance
• Negative Sentiment: Structural revenue headwinds — declining COVID product sales, patent‑cliff impacts and an expected ~$1.5B hit in coming periods were cited by analysts as reasons the stock can lag despite beats. FT: vaccines and patent pressures weigh on sales
• Negative Sentiment: Mixed investor reaction to obesity data — some coverage flagged safety/signal questions and that Pfizer’s monthly dosing may still face tough competition from established GLP‑1 leaders (Lilly, Novo); that uncertainty contributed to earlier share weakness. MSN: mixed response to weight‑loss data
• Negative Sentiment: Program shifts — Pfizer and partners have paused certain modRNA shingles ambitions, showing the company is re‑prioritizing pipeline choices; such changes can be seen as conservative but remove near‑term optionality. TipRanks: Pfizer/BioNTech pause modRNA shingles ambitions

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.